ProCE Banner Activity

LEVI Syndrome: Characterization of Long-Acting Early Viral inhibition During PrEP With LA CAB

Capsule Summary
Conference Coverage

LEVI—a phenomenon described in the few people who became infected while receiving LA CAB for PrEP—was characterized by delays in HIV detection and INSTI resistance. No INSTI resistance was observed if the infection occurred more than 6 months from the last injection.

Released: February 27, 2023

Expiration: February 26, 2024



Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

Merck & Co., Inc.

ViiV Healthcare